business plans and objectives on the clinical development of clinical and preclinical pipeline, including the therapeutic potential, clinical benefits and safety thereof, Sanofi’s expansion of ...

Xencor Inc . (NASDAQ:XNCR), a biopharmaceutical company specializing in innovative therapies for immunology and oncology, ...

Pipeline Updates and 2025 Anticipated Milestones ... program through the completion of Phase 1 clinical development, which will be funded by Lilly. Lilly will then be responsible for subsequent ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

This valuation reflects both the potential of its pipeline and the inherent risks associated with clinical-stage drug development. The biotechnology sector, particularly in oncology and immunology ...

Promising tuberculosis pipeline therapies such as MTBVAC ... with the global biopharma company GSK to accelerate the clinical development of alpibectir (BVL-GSK098) for the treatment of ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

Eleva, a pioneer in unlocking biologics based on a breakthrough manufacturing platform, and 3PBIOVIAN, a contract development ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...